这项发表在《自然》上的研究，通过层层递进的逻辑，为我们解开了一个长期存在的谜题。它确立了“肠道-肿瘤轴”中T细胞可塑性的核心地位，提出了“抗原模拟”作为治疗策略的可行性，并强调了微生物种类的选择至关重要。

肿瘤免疫检查点抑制剂（immune checkpoint inhibitors，ICIs）的广泛应用显著改善了非小细胞肺癌、黑色素瘤等多种晚期实体肿瘤患者生存预后，但随之而来的免疫相关不良反应（immune-related adverse ...

Cancer represents a key challenge in medical science, manifesting as a disease where the immune system fails to recognize and eliminate tumor cells. The phenomenon of immune evasion by cancer cells ...

More than two-thirds of deaths from ovarian cancer are attributable to high-grade serous carcinoma. In one particularly ...

Degrader of cancer protein IDO1 prevents cancer immune suppression by cancer and offers promising strategy to support ...

Immune Checkpoint Blockade (ICB) has reshaped cancer care and can deliver durable remission in malignancies such as melanoma and non-small cell lung cancer.

ImmunityBio recently reported positive clinical data from its ANKTIVA (nogapendekin alfa inbakicept) program in non-small ...

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...

In patients who developed cutaneous immune-related adverse events, researchers compared outcomes for those who received ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...